Krystal Biotech (KRYS) Current Leases (2019 - 2026)

Krystal Biotech has disclosed Current Leases across 8 years of filings, most recently posting $1.8 million for Q1 2026.

• Current Leases for Q1 2026 came in at $1.8 million, up 32.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 32.16% YoY), and the FY2025 annual result was $1.8 million, up 45.52% from the prior year.
• Current Leases came in at $1.8 million for Q1 2026 at Krystal Biotech, up from $1.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.8 million in Q1 2026 to a low of $1.2 million in Q4 2024.
• The 5-year median for Current Leases is $1.5 million (2023), against an average of $1.5 million.
• Across the five-year window, Current Leases soared 117.75% in 2022 and retreated 17.44% in 2024, its largest moves.
• Krystal Biotech's Current Leases stood at $1.6 million in 2022, then declined by 5.57% to $1.5 million in 2023, then declined by 17.44% to $1.2 million in 2024, then soared by 45.52% to $1.8 million in 2025, then rose by 1.64% to $1.8 million in 2026.
• The last three Current Leases figures came in at $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.